The routine histological investigation of axillary lymph nodes for metastatic breast cancer

1984 ◽  
Vol 143 (3) ◽  
pp. 187-191 ◽  
Author(s):  
F. Hartveit
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Lymph Nodes ◽  
Metastatic Breast ◽  
Axillary Lymph Nodes ◽  
Axillary Lymph ◽  
Histological Investigation

scholarly journals Prostate-Specific Ets (PSE) factor: a novel marker for detection of metastatic breast cancer in axillary lymph nodes

2002 ◽  
Vol 86 (6) ◽  
pp. 899-904 ◽  
Author(s):  
M Mitas ◽  
K Mikhitarian ◽  
L Hoover ◽  
M A Lockett ◽  
L Kelley ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Lymph Nodes ◽  
Metastatic Breast ◽  
Axillary Lymph Nodes ◽  
Axillary Lymph

scholarly journals Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph nodes

2018 ◽  
Vol 128 (4) ◽  
pp. 1355-1370 ◽  
Author(s):  
Ikram Ullah ◽  
Govindasamy-Muralidharan Karthik ◽  
Amjad Alkodsi ◽  
Una Kjällquist ◽  
Gustav Stålhammar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Lymph Nodes ◽  
Evolutionary History ◽  
Metastatic Breast ◽  
Axillary Lymph Nodes ◽  
Axillary Lymph ◽  
History Of

scholarly journals Breast Cancer with Internal Mammary Node Metastases: A Case Presented in a Tumor Board Session and Decision Making

2019 ◽  
pp. 156-160
Author(s):  
Léamarie Meloche-Dumas ◽  
Erica Patocskai ◽  
Kerianne Boulva ◽  
Moishe Liberman ◽  
Younan Rami
Keyword(s):  
Breast Cancer ◽  
Lymph Nodes ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Metastatic Breast ◽  
Tumor Board ◽  
Axillary Lymph Nodes ◽  
Axillary Lymph ◽  
Internal Mammary Chain ◽  
Internal Mammary

Background: There are several therapeutic options available for breast cancer treatment, now incorporating innovative targeted molecular therapies. Metastatic breast cancer is usually treated with chemotherapy and/or hormonotherapy. Surgery has not been shown to improve survival. Adjuvant radiotherapy (RT) has been proven to be effective in the treatment of locally advanced breast cancer, reducing locoregional recurrence. The optimal treatment of internal mammary lymph nodes (IMN) metastases remains controversial. Case presentation: A 48-year-old woman was diagnosed with invasive breast cancer with ipsilateral metastases to axillary lymph nodes and a contralateral IMN metastasis. This case was presented twice during the tumor board sessions of the Surgical Oncology Service at the Centre hospitalier de l'Université de Montréal (CHUM), Montréal, Canada. Question: Does the internal mammary chain (IMC) dissection could be used as a treatment approach in breast cancer with IMC metastasis? Conclusion: Internal mammary chain dissection should be discussed in tumor board sessions on a case-by-case basis. There are no strong guidelines on the management of IMN metastasis in breast cancer, but there is growing evidence that these women should be treated with curative intent.

MicroRNAs involved in immune response as prognostic markers in early and metastatic breast cancer.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e15528-e15528
Author(s):  
Chara Papadaki ◽  
Konstantina Thomopoulou ◽  
George Koronakis ◽  
Alexia A Monastirioti ◽  
Maria A. Papadaki ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Immune Response ◽  
Lymph Nodes ◽  
Immune Escape ◽  
Metastatic Breast ◽  
Axillary Lymph Nodes ◽  
Axillary Lymph ◽  
Circulating Mirnas ◽  
Early Relapse ◽  
Expression Levels

e15528 Background: MicroRNAs (miRNAs) are involved in the regulation of immune response and have an important role in immune escape. We analyzed the expression levels of plasma miR-10b, miR-126, miR-19α, miR-20α and miR-155, which regulate tumor-immune interactions and investigated their prognostic implications in patients with early (eBC) and metastatic (mBC) breast cancer. Methods: Blood samples were obtained before treatment from 140 and 64 patients with eBC and mBC, respectively. Plasma miRNA expression levels were assessed by qRT-PCR and expression was classified as high or low according to the median values. Results: A panel of four miRNAs (miR-19a, miR-20a, miR-126 and miR-155) could discriminate eBC from mBC (AUC 0.802, p < 0.001). In early disease, miR-10b (p = 0.022) and miR-155 (p = 0.005) expression was lower in relapsed (n = 46) compared to non-relapsed (n = 94) patients; miR-155 expression along with lymph node infiltration and tumor grade had increased ability to predict relapse (AUC = 0.775; p = 0.003). In addition, miR-10b (p = 0.015), miR-19a (p = 0.003), miR-20a (p = 0.012), miR-126 (p = 0.001) and miR-155 (p < 0.001) expression levels were lower in patients with early relapse (relapse at ≤2 years). MiR-155 and miR-19a had the highest performance in discriminating early relapse (AUC 0.855; p < 0.001 and AUC = 0.729; p = 0.003, respectively), whereas, combined mir-155 and miR-19a expression further increased the accuracy of prediction (AUC = 0.867; p < 0.001). In eBC, the number of infiltrated lymph nodes and low miR-10b independently predicted for shorter DFS (p = 0.001 and p = 0.03, respectively) and axillary lymph nodes for shorter OS (p = 0.003). In the triple negative subgroup, low miR-155 strongly predicted for shorter DFS (p = 0.037). In mBC, recurrent disease and low miR-10b expression independently predicted for shorter PFS (p = 0.001 and p = 0.017, respectively), whereas performance status of 2 independently predicted for shorter OS (p = 0.03). Conclusions: Deregulated expression of circulating miRNAs involved in tumor-immune interactions can discriminate disease status in BC and independently predicts for patients’ outcome in early and mBC. Our results further support the notion that circulating miRNAs represent a useful prognostic tool in patients with BC.

Sign in / Sign up

Export Citation Format

Share Document